Read More Healthcare Industry News Artivion (NYSE: AORT) begins pivotal Arcevo LSA trial: Could this hybrid stent unlock an $80m U.S. market? Artivion begins pivotal ARTIZEN trial with first patient treated using Arcevo LSA. Find out how this hybrid stent could transform aortic arch surgery. byVenkateshNovember 6, 2025